Macrophages define the invasive microenvironment in breast cancer

被引:332
作者
Pollard, Jeffrey W. [1 ]
机构
[1] Albert Einstein Coll Med, Dept Dev & Mol Biol, Albert Einstein Canc Ctr, Ctr Reprod Biol & Womens Hlth, Bronx, NY 10461 USA
关键词
metastasis; CSF-1; EGF; VEGF; chemotaxis;
D O I
10.1189/jlb.1107762
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
In many human cancers, the abundance of macrophages in the tumor microenvironment is correlated with poor prognosis. Experimental evidence for the causal relationship between macrophages and poor prognosis came from mouse models of breast cancer in which genetic ablation of macrophages resulted in attenuation of tumor progression and metastasis, and premature recruitment to hyperplastic lesions accelerated these processes. Malignancy is defined by the invasion of tumor cells into the stroma, a process that allows escape of these cells into the circulation and dissemination to distant sites. In this review, I argue that macrophages are recruited to the invasive front by expression of tumor-derived chemotactic factors and in response to the disruption of the basement membrane. At this invasive site, macrophages enhance tumor cell migration and invasion through their secretion of chemotactic and chemokinetic factors including epidermal growth factor (EGF). They promote angiogenesis by the synthesis of angiogenic factors including vascular endothelial growth factor (VEGF), and they remodel the extracellular matrix and in particular, regulate collagen fibrillogenesis. A combination of these factors provides a triple-whammy, as the more mobile and invasive tumor cells track along collagen fibers that are also anchored to blood vessels, which are fabricated at sites of invasion and through which macrophages potentiate tumor cell intravasation. All of these activities suggest that macrophage functions are significant targets for the generation of novel therapeutics that should improve the current cytotoxic armamentarium.
引用
收藏
页码:623 / 630
页数:8
相关论文
共 73 条
[1]   Colony-stimulating factor-1 blockade by antisense oligonucleotides and small interfering RNAs suppresses growth of human mammary tumor xenografts in mice [J].
Aharinejad, S ;
Paulus, P ;
Sioud, M ;
Hofmann, M ;
Zins, K ;
Schäfer, R ;
Stanley, ER ;
Abraham, D .
CANCER RESEARCH, 2004, 64 (15) :5378-5384
[2]   Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1 [J].
Barleon, B ;
Sozzani, S ;
Zhou, D ;
Weich, HA ;
Mantovani, A ;
Marme, D .
BLOOD, 1996, 87 (08) :3336-3343
[3]   TGF-β signaling in fibroblasts modulates the oncogenic potential of adjacent epithelia [J].
Bhowmick, NA ;
Chytil, A ;
Plieth, D ;
Gorska, AE ;
Dumont, N ;
Shappell, S ;
Washington, MK ;
Neilson, EG ;
Moses, HL .
SCIENCE, 2004, 303 (5659) :848-851
[4]   The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies [J].
Bingle, L ;
Brown, NJ ;
Lewis, CE .
JOURNAL OF PATHOLOGY, 2002, 196 (03) :254-265
[5]   Reduced inflammation in the tumor microenvironment delays the accumulation of myeloid-derived suppressor cells and limits tumor progression [J].
Bunt, Stephanie K. ;
Yang, Linglin ;
Sinha, Pratima ;
Clements, Virginia K. ;
Leips, Jeff ;
Ostrand-Rosenberg, Suzanne .
CANCER RESEARCH, 2007, 67 (20) :10019-10026
[6]  
CECCHINI MG, 1994, DEVELOPMENT, V120, P1357
[7]   Intravital imaging of cell movement in tumours [J].
Condeelis, J ;
Segall, JE .
NATURE REVIEWS CANCER, 2003, 3 (12) :921-930
[8]   Macrophages: Obligate partners for tumor cell migration, invasion, and metastasis [J].
Condeelis, J ;
Pollard, JW .
CELL, 2006, 124 (02) :263-266
[9]   Inflammatory mast cells up-regulate angiogenesis during squamous epithelial carcinogenesis [J].
Coussens, LM ;
Raymond, WW ;
Bergers, G ;
Laig-Webster, M ;
Behrendtsen, O ;
Werb, Z ;
Caughey, GH ;
Hanahan, D .
GENES & DEVELOPMENT, 1999, 13 (11) :1382-1397
[10]   MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis [J].
Coussens, LM ;
Tinkle, CL ;
Hanahan, D ;
Werb, Z .
CELL, 2000, 103 (03) :481-490